Fig. 2.

Kaplan–Meier estimate of the progression-free survival in the two treatment groups. Since there was one patient in the S-1 monotherapy group who had a long duration of response (21.7 months), the PFS curve was thus longer for the S-1 group. However, the median PFS was longer in the irinotecan plus S-1 group than in the S-1 monotherapy group. PFS progression free survival, CI confidence interval, HR hazard ratio